Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

DexCom Inc (DXCM)

NASDAQ
Currency in USD
Disclaimer
69.21
-0.35(-0.50%)
Closed
After Hours
69.25+0.04(+0.06%)
DXCM Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 10 days
Fair Value
Day's Range
69.0670.02
52 wk Range
62.34142.00
Prev. Close
69.56
Open
69.98
Day's Range
69.06-70.02
52 wk Range
62.34-142
Volume
3,942,344
Average Volume (3m)
5,703,101
1-Year Change
-9.16%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
DXCM Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
95.69
Upside
+38.26%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

InvestingPro Research for DexCom Inc


CGM Market Leade
DexCom navigates challenges in the continuous glucose monitoring industry while expanding its reach with the launch of Stelo CGM for non-insulin users
Financial Hurdles
Explore DexCom's mixed financial performance, including revenue shortfalls and revised guidance, alongside strategies to overcome sales force disruptions
Competitive Landscape
Delve into DexCom's efforts to maintain market share amid intensifying competition, particularly from Abbott Laboratories in the DME and AID markets
Growth Prospects
Analyst price targets range from $80 to $130, reflecting diverse views on DexCom's potential in the expanding global diabetes care market of 550 million patients

DexCom Inc Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
41.6x−4.2x−0.6x
PEG Ratio
0.480.000.00
Price/Book
11.4x2.4x2.6x
Price / LTM Sales
7.0x1.7x3.2x
Upside (Analyst Target)
37.3%21.6%46.9%
Fair Value Upside
Unlock21.1%7.9%Unlock

People Also Watch

39.66
MGM
+0.18%
52.87
LVS
+1.65%
150.50
EXPE
-0.24%
66.63
CVS
-0.33%

FAQ

What Is the DexCom (DXCM) Stock Price Today?

The DexCom stock price today is 69.21

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 27.73B.

What is DexCom Earnings Per Share?

The DexCom EPS is 1.71.

What Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on 23 Oct 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.